NCT05713006
- Conditions
- ALK Gene Mutation, Bronchial Neoplasms, Carcinoma, Bronchogenic, +9 more
- Locations
-
- Thoracic Oncology Unit and Personalized Medicine Laboratory, Instituto Nacional de Cancerología Mexico City, Mexico
Clinical trial condition
ALK Gene Mutation
Explore clinical trials studying ALK Gene Mutation. Study availability and eligibility vary by location and protocol.
12 public trials
7 recruiting studies
ALK Gene Mutation trial results
NCT03042221
- Conditions
- ALK Gene Mutation, BRAF V600E, Bronchial Neoplasms, +13 more
- Locations
-
- University of Colorado, Cancer Center Aurora, Colorado, United States
Recruiting
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
NCT04322890
- Conditions
- ALK Gene Mutation, Bronchial Neoplasms, Carcinoma, Bronchogenic, +12 more
- Locations
-
- Yongchang Zhang Changsha, Hunan, China
NCT06234579
- Conditions
- ALK Gene Mutation, ALK Sensitizing Mutation, Bronchial Neoplasms, +10 more
- Locations
-
- Fondazione Policlinico Gemelli IRCCS Rome, Italy
Recruiting
Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK
NCT05266846
- Conditions
- ALK Gene Mutation, Adenocarcinoma, Adenocarcinoma of Lung, +10 more
- Locations
-
- Hunan Cancer Hospital Changsha, Hunan, China
- Conditions
- ALK Gene Mutation, Non Small Cell Lung Cancer Metastatic
- Locations
-
- Centro di Riferimento Oncologico (CRO) IRCCS Aviano, Italy
- Azienda Ospedaliero-Universitaria Careggi Oncologia Medica Florence, Italy
- Azienda USL Toscana Nord Ovest Oncologia Medica, Ospedale Versilia Lido di Camaiore, Italy
- Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino amadori" Meldola, Italy
NCT05724004
- Conditions
- ALK Gene Mutation, Bronchial Neoplasms, Carcinoma, Bronchogenic, +12 more
- Locations
-
- Karolinska University Hospital Stockholm, Sweden
Not yet recruiting
Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC
NCT07674524
- Conditions
- ALK Gene Mutation, ALK-positive, Bronchial Neoplasms, +16 more
- Locations
-
- Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
Active, not recruiting
Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies
NCT05370469
- Conditions
- ALK Gene Mutation, BRAF, EGFR, +13 more
- Locations
-
- University of Virginia Charlottesville, Virginia, United States
Active, not recruiting
Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)
NCT05200481
- Conditions
- ALK Gene Mutation, Bronchial Neoplasms, Carcinoma, Bronchogenic, +9 more
- Locations
-
- CHU d'Angers Angers, France
- CHU Besançon - Hôpital J. MINJOZ Besançon, France
- Hôpital APHP Ambroise Paré Boulogne, France
- Hospices Civils de Lyon - Hôpital Louis Pradel Bron, France